Vaginal Dryness and GSM: The Symptom Nobody Talks About Enough

The short answer: vaginal dryness, discomfort, painful sex and recurrent urinary symptoms in menopause are part of a treatable medical condition called genitourinary syndrome of menopause (GSM), caused by falling estrogen (oestrogen) thinning the vaginal and urinary tissues. Unlike hot flashes (hot flushes), which tend to ease over time, GSM usually worsens without treatment, so waiting it out is the wrong strategy. The most effective treatment, low-dose local vaginal estrogen, is safe for the large majority of women, including many who cannot take systemic hormones, and non-hormonal moisturisers and lubricants help too. The single biggest barrier is silence: most women who have it have never told their doctor. It is common, but common is not the same as untreatable.

This is one of the most under-discussed symptoms in all of menopause care, and the silence has a real cost. GSM affects the majority of postmenopausal women and a significant proportion of perimenopausal ones, yet surveys consistently find that only a minority ever raise it with a clinician. Many have been told, or have concluded, that it is simply a part of ageing to be endured. It is not. The tissues involved respond well to treatment, often dramatically, which is exactly why it is worth pushing past the embarrassment to have the conversation.

What GSM actually is

Genitourinary syndrome of menopause is the modern umbrella term, adopted in 2014 to replace the narrower and more clinical-sounding “vulvovaginal atrophy”, precisely because the older words undersold how much it affects and how much it matters. GSM covers the whole cluster of changes that estrogen loss produces in the genital and urinary tissues: vaginal dryness, burning and itching; loss of elasticity and a feeling of tightness; discomfort or pain during sex (dyspareonia); light bleeding or spotting after sex; and a set of urinary symptoms including urgency, frequency, discomfort passing urine, and more frequent urinary tract infections (UTIs).

Grouping these together is not just tidy naming; it reflects a shared cause. The vagina, vulva, urethra and bladder base all depend on estrogen, so when estrogen falls they change together. This is why a woman might see her doctor about recurrent UTIs and never connect them to the vaginal dryness she has quietly lived with, when in fact they are two faces of the same underlying process. Recognising GSM as one condition helps you describe the full picture and get it treated properly.

Why estrogen matters here

Estrogen keeps the vaginal and vulval tissues thick, elastic, well-lubricated and well supplied with blood. It also maintains an acidic vaginal environment that favours protective lactobacilli bacteria and keeps harmful bacteria in check. As estrogen declines, first fluctuating in perimenopause, then settling low after menopause, the tissue becomes thinner, drier, less elastic and more fragile, and the vaginal pH rises, shifting the balance of bacteria in a way that raises the risk of irritation and infection. The same thinning affects the urethra and bladder, which is why urinary symptoms travel with the vaginal ones.

The crucial clinical point follows directly from the mechanism: because the driver is a sustained loss of estrogen rather than a temporary fluctuation, GSM typically progresses rather than resolves if left alone. This is the opposite of the trajectory of hot flashes, which tend to fade over the years. Understanding this difference is genuinely important, because it means “wait and see” is not a neutral choice with GSM; the tissues generally continue to change until something is done. That is the strongest argument for addressing it proactively rather than hoping it passes.

What treatment is available

Local vaginal estrogen is the most evidence-supported treatment for GSM, and it works because it targets the root cause directly. Delivered as a cream, pessary, tablet or a slow-release ring placed in the vagina, it restores the thickness, elasticity, lubrication and healthy pH of the tissue over a few weeks to months. Because the dose is very low and acts locally, very little is absorbed into the rest of the body, which is why menopause societies regard it as appropriate for the large majority of women, including many who cannot or choose not to take systemic hormone therapy. It is used long term, because symptoms return if it is stopped, and it can be combined with systemic HRT if you take that for other symptoms. Our explainer on what HRT involves covers how the two differ.

Non-hormonal options are valuable both on their own and alongside estrogen. Vaginal moisturisers, used regularly (typically several times a week) rather than only around sex, hydrate the tissue and improve day-to-day comfort. Lubricants, used at the time of sex, reduce friction and pain. These do not reverse the underlying tissue changes the way estrogen does, but they provide real relief and are a sensible first step, especially while you arrange to see a doctor. Water- or silicone-based products are gentler than those with irritating additives.

Other treatments exist for specific situations. A vaginal DHEA preparation and an oral medication called ospemifene are options in some countries for women who cannot use or do not want vaginal estrogen. Vaginal laser treatments are marketed for GSM but currently have limited high-quality evidence and are not first-line. A clinician can help you match the option to your circumstances and preferences.

The connection to sex, and to the rest of your life

GSM is not only a comfort issue; it quietly affects intimacy and confidence. When sex becomes painful, desire understandably follows it downwards, and couples can drift into avoidance without ever naming why. Treating the physical cause frequently restores comfort and, with it, interest, which is why GSM and libido are so intertwined; we explore that overlap in our guide to libido in perimenopause. The point worth internalising is that painful sex in midlife is a medical symptom with effective treatment, not a relationship failing or an inevitable loss.

The urinary side deserves the same seriousness. Recurrent UTIs are miserable and, in older women, carry real risks, and local vaginal estrogen has good evidence for reducing their frequency by restoring the protective tissue and bacterial balance. If you are stuck in a cycle of repeated UTIs, treating GSM may do more than another course of antibiotics, so it is well worth raising the vaginal and hormonal angle with your doctor rather than treating each infection in isolation.

How to raise it, and why you should

The reasons women give for not mentioning GSM are consistent: embarrassment, the assumption that it is just ageing, and simply not knowing that effective treatment exists. Sometimes a doctor has even confirmed it is “normal”, which is true in the sense of common, but common and untreatable are not the same thing, and that phrasing has left many women suffering needlessly for years.

You do not need to find the perfect words. Saying “I have vaginal dryness and discomfort, and I think it might be treatable” is enough to open the door, and if it is easier, add it to a written symptom list and hand it over. Specific prompts to raise: sex has become uncomfortable or painful; you are getting recurrent UTIs without an obvious cause; or dryness, itching or urinary urgency is affecting your daily life or relationship. Our guide to getting the most out of a doctor’s appointment has more on advocating for yourself if the response is dismissive. This is a legitimate medical symptom with legitimate, effective treatment, and you are entitled to both.

Frequently Asked Questions

Is vaginal dryness normal in menopause?

It is very common, affecting the majority of postmenopausal women, but common does not mean untreatable or something you have to simply accept. GSM is a recognised medical condition with effective treatments, most notably local vaginal estrogen. Most women do not have to manage it unsupported, and treating it usually improves comfort considerably.

Does local vaginal estrogen affect the rest of my body?

It is designed to act on the vaginal and surrounding tissues with only minimal absorption into the bloodstream, which is why menopause societies consider it appropriate for the large majority of women, including many who cannot take systemic hormone therapy. If you have a specific concern, such as a history of hormone-sensitive cancer, discuss it with your doctor, but for most women the safety profile is very reassuring.

Can GSM cause urinary symptoms?

Yes. Urinary urgency, frequency, discomfort passing urine and more frequent UTIs are all part of the GSM spectrum, because the urethra and bladder base depend on estrogen just as the vagina does. If you have these symptoms, raise them alongside any vaginal ones, as treating the underlying GSM, often with local vaginal estrogen, can reduce recurrent UTIs.

Will GSM get better on its own?

Usually not. Unlike hot flashes, which tend to ease over time, GSM typically worsens without treatment because it is driven by a sustained loss of estrogen rather than a passing fluctuation. This is one of the strongest reasons to address it proactively rather than waiting, since the tissue changes generally continue until treated.

What can I use in the meantime before seeing a doctor?

Vaginal moisturisers used regularly, several times a week rather than only around sex, hydrate the tissue and improve day-to-day comfort, and lubricants reduce friction and pain during sex. Both are widely available without prescription and can provide meaningful relief while you arrange treatment. Choose gentle, water- or silicone-based products without irritating fragrances.

Is it safe to use vaginal estrogen long term?

For most women, yes. Because it is low-dose and local, it is intended for ongoing use, and stopping it usually allows symptoms to return, since the underlying estrogen loss persists. Long-term use is considered appropriate by menopause guidelines for the majority of women. As with any treatment, your own history should be discussed with your clinician, who can tailor the approach to you.

more